Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma Pharmaceutical Investing
Genetic Technologies Limited Announces Further Collaborative Research with The University of Melbourne Genetics Investing
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Biotech Investing
Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2017 Financial Results Genetics Investing
Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy Genetics Investing
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update Genetics Investing